Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersNo recent work listed

Dick J. Richel

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5111429119, A5112083838. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: 2 papers · 2014: 3 papers · 2015: 2 papers · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: 1 paper

Papers 13

  1. Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers13194869↗
  2. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. Co-author DOI 10.1186/s12885-017-3131-x↗
  3. Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice. Co-author DOI 10.2119/molmed.2016.00214↗
  4. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00280-015-2730-y↗
  5. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Co-author DOI 10.1016/s1470-2045(15)00027-3↗
  6. Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. Co-author DOI 10.1002/ijc.28726↗
  7. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. Co-author DOI 10.1002/path.4411↗
  8. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Co-author DOI 10.1016/j.ctrv.2013.04.004↗
  9. A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced panc… First author DOI 10.1007/s10637-012-9802-1↗
  10. Protease-activated receptor-2 induces migration of pancreatic cancer cells in an extracellular ATP-dependent manner. Co-author DOI 10.1111/jth.12361↗
  11. Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. First author DOI 10.1016/j.radonc.2010.10.016↗
  12. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Co-author DOI 10.1016/s1470-2045(11)70004-3↗
  13. mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. Last author DOI 10.1200/jco.2010.32.7825↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Johanna W. Wilmink · 5 shared papers, 2013–2021 · strength 0.32
  2. C. Arnold Spek · 5 shared papers, 2011–2017 · strength 0.25
  3. Kun Shi · 4 shared papers, 2013–2017 · strength 0.22
  4. Karla C. S. Queiroz · 4 shared papers, 2011–2014 · strength 0.17
  5. Sil Kordes · 3 shared papers, 2013–2015 · strength 0.15
  6. Heinz‐Josef Klümpen · 3 shared papers, 2011–2015 · strength 0.13
  7. Remy Klaassen · 1 shared paper, 2021 · strength 0.12
  8. Nienke Petronella Maria Wassenaar · 1 shared paper, 2021 · strength 0.12
  9. Esther N. Pijnappel · 1 shared paper, 2021 · strength 0.12
  10. Aart Johannes Nederveen · 1 shared paper, 2021 · strength 0.12
  11. Hanneke W.M. van Laarhoven · 1 shared paper, 2021 · strength 0.12
  12. Oliver J. Gurney‐Champion · 1 shared paper, 2021 · strength 0.12
  13. Helene Damhofer · 1 shared paper, 2017 · strength 0.08
  14. Jan H.M. Schellens · 1 shared paper, 2015 · strength 0.06
  15. Donald Richards · 1 shared paper, 2017 · strength 0.05
  16. Berta Laquente · 1 shared paper, 2017 · strength 0.05
  17. George Kim · 1 shared paper, 2017 · strength 0.05
  18. Emiliano Calvo · 1 shared paper, 2017 · strength 0.05
  19. Tudor–Eliade Ciuleanu · 1 shared paper, 2017 · strength 0.05
  20. Stefano Cascinu · 1 shared paper, 2017 · strength 0.05
  21. Daniel D. Von Hoff · 1 shared paper, 2017 · strength 0.05
  22. Marc Ychou · 1 shared paper, 2014 · strength 0.05
  23. Volker Heinemann · 1 shared paper, 2014 · strength 0.05
  24. Michel Pierre Ducreux · 1 shared paper, 2014 · strength 0.05
  25. Michele Reni · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.